Evidence map›Paper›PMID 41978518›Full record

ArticleAdvanced healthcare materials2026

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury.

Jialing Tang, Wing Yan Chung, Serena M Pulente, Yubin Lei, Khang Nguyen, Eddie Tam, Nadya M Morrow, Ilka Lorenzen-Schmidt, Fengxia Xiao, Augusto Zani and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jialing TangDepartment of Biology, York University, Toronto, Ontario, Canada.
Wing Yan ChungDepartment of Biology, York University, Toronto, Ontario, Canada.
Serena M PulenteThe Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, The University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Yubin LeiDepartment of Biology, York University, Toronto, Ontario, Canada.
Khang NguyenDepartment of Biology, York University, Toronto, Ontario, Canada.
Eddie TamDepartment of Biology, York University, Toronto, Ontario, Canada.
Nadya M MorrowThe Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, The University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Ilka Lorenzen-SchmidtThe Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, The University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Fengxia XiaoKidney Research Center, Department of Cellular and Molecular Medicine, The Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, Ontario, Canada.
Augusto ZaniDevelopmental and Stem Cell Biology Program, Peter Gilgan Centre For Research and Learning, The Hospital for Sick Children, Toronto, Ontario, Canada.
Dylan BurgerKidney Research Center, Department of Cellular and Molecular Medicine, The Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, Ontario, Canada.
Hye Kyoung SungDepartment of Biology, York University, Toronto, Ontario, Canada.
Erin E MulvihillThe Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, The University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Gary SweeneyDepartment of Biology, York University, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-1946-1347

Funding

CIHR
6 · The paper itself

Abstract

Ischemic heart disease is a leading cause of global morbidity and mortality, with more effective clinical therapies needed to mitigate cardiac ischemic injury. Extracellular vesicles (EVs) mediate intercellular communication in cardiac pathophysiology. Adiponectin mediates cardioprotective effects yet its relationship with EVs biology remains unexplored. We investigated whether ALY688, an adiponectin receptor agonist, modulates EV biogenesis and cargo to confer cardioprotection in a mouse model of myocardial infarction (MI). ALY688 (15 mg/kg daily for 28 days) significantly attenuated MI-induced cardiac dysfunction, reduced infarct size, and decreased fibrotic scar in both lean mice on standard chow and obese mice fed a high-fat diet. Plasma EVs were isolated and while MI reduced circulating EV numbers, ALY688 restored EV production and enhanced loading with bioactive adiponectin. In addition, proteomic analysis revealed ALY688-shaped EVs were enriched in metabolism regulated proteins. The direct functional effects and mechanisms of EV action were examined in iPSC-derived cardiomyocytes and H9c2 cells. EV from ALY688 treated mice (EV

Indexed as

Cardiotonic AgentsExtracellular VesiclesMyocardial IschemiaReceptors, AdiponectinAdiponectinAnimalsApoptosisAutophagyCell LineDisease Models, AnimalMaleMiceMice, Inbred C57BLMyocardial InfarctionMyocytes, CardiacAdiponectinCardiotonic AgentsReceptors, Adiponectinadiponectincardiac protectionextracellular vesiclesmyocardial ischemia

Identifiers

PMID41978518
PMCPMC13279854

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.